ARS Pharmaceuticals, Inc. (SPRY) Return on equity 2022–2025
ARS Pharmaceuticals, Inc. (SPRY) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-149.9%FY2025 · since FY2022: -12.7% → -149.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -149.9% | -153.0 pp |
| FY2024 | 3.1% | +26.7 pp |
| FY2023 | -23.6% | -10.8 pp |
| FY2022 | -12.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRY financial trends
SPRY RevenueSPRY Net incomeSPRY Net marginSPRY Gross profitSPRY Gross marginSPRY Operating incomeSPRY Operating marginSPRY Operating cash flowSPRY Free cash flowSPRY Capital expendituresSPRY Stock buybacksSPRY Dividends paidSPRY Total assetsSPRY Total liabilitiesSPRY Shareholders’ equitySPRY overview →